-
Nu.Q® Technology
Our technology detects characteristic epigenetic changes in nucleosomes that occur from the earliest stages of cancer, sepsis and other diseases.
-
- Our Tests
- Human Health
-
Nu.Q® NETs
Nu.Q® NETs is a groundbreaking CE-marked diagnostic solution that clinicians can use to detect NETosis.
-
Nu.Q® Discover
Buy our Nu.Q® Discover H3.1 Research Use Only Assay
- Animal Health
-
Nu.Q® Vet Cancer Test
Nu.Q® Vet Cancer Test is an affordable, accessible blood test that detects cancer in dogs.
-
- Our Pipeline Development
-
Nu.Q® Cancer
We are developing a range of blood-based assays with potential applications beyond cancer detection.
-
Capture-Seq™
We have developed Capture-Seq™, a novel liquid biopsy method designed to isolate and analyze pure circulating tumor-derived DNA (ctDNA) from blood samples.
Did you know that cancer is the leading cause of death in dogs over the age of two? 50% of all dogs will be diagnosed with cancer in their lifetimes. As with humans, early detection is key for better outcomes in these dogs. Watch this short video, featuring Volition CMO Heather Wilson-Robles, as she introduces our Nu.Q® Vet Cancer Test and its benefits.
Related Articles
-
Press Releases
Volition Announces Submission of Manuscript for Nu.Q® Vet Cancer Test in Cats. The publication of this study in a peer reviewed journal is expected subsequently to unlock a $5 million contractual milestone payment
-
Press Releases
Volition Announces First Ever Automated Nu.Q® Vet Cancer Test with Fujifilm Vet Systems
- Share
- Tweet
- Share on Facebook
- Share
Subscribe for Volition product updates.
Or, click here for Investor Updates and press releases.
"*" indicates required fields
